gms | German Medical Science

102. Jahrestagung der DOG

Deutsche Ophthalmologische Gesellschaft e. V.

23. bis 26.09.2004, Berlin

A randomized, prospective dosage-finding study of intravitreal Triamcinolone Acetonide on diabetic maculopathy and exudative AMD

Meeting Abstract

  • corresponding author U.H.M. Spandau - Department of Ophthalmology, Evangelical Stift, Koblenz, Germany
  • M. Derse - Department of Ophthalmology, Evangelical Stift, Koblenz, Germany
  • P. Schmitz-Valckenberg - Department of Ophthalmology, Evangelical Stift, Koblenz, Germany
  • C. Papoulis - Department of Ophthalmology, Evangelical Stift, Koblenz, Germany
  • J.B. Jonas - Department of Ophthalmology, University of Mannheim

Evidenzbasierte Medizin - Anspruch und Wirklichkeit. 102. Jahrestagung der Deutschen Ophthalmologischen Gesellschaft. Berlin, 23.-26.09.2004. Düsseldorf, Köln: German Medical Science; 2004. Doc04dogFR.13.09

The electronic version of this article is the complete one and can be found online at:

Published: September 22, 2004

© 2004 Spandau et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.




To evaluate efficacy of different dosages of intravitreal triamcinolone acetonide on diabetic maculopathy and exsudative age related maculopathy (ARMD).


The prospective, randomized, double masced study included 60 eyes of 60 patients with diabetic maculopathy (n=32 eyes) or exsudative age related macular maculopathy (AMD) (n=28). A randomized dosage of 4mg, 8mg or 25mg crystalline triamcinolone acetonide was injected. Main outcome measure was the visual acuity (ETDRS) after 1, 3 and 6 months.


Without regard to dosage, visual acuity gain was higher in patients with diabetic maculopathy than ARMD. Treatment response was immediate and significantly (p<0.05) earlier in patients with diabetic maculopathy (1 week follow-up, all dosages) than in patients with AMD (1 month follow-up, all dosages). After 3 months follow-up, patients with diabetic maculopathy had a significant higher increase in VA after injection of 25mg than after injection of 8mg and 4mg. After 6 months all dosages demonstrated a VA loss (4mg and 8mg > 25mg). Patients with ARMD showed no significant increase in VA with all dosages.


An intravitreal triamcinolone acetonide injection results in a higher VA increase in eyes with diabetic maculopathy than in eyes with ARMD. After a follow-up of 6 months, the treatment response occurs faster and longer lasting after an injection of 25mg than 8mg or 4mg.